• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioNanomatrix changes name to BioNano Genomics

BioNanomatrix changes name to BioNano Genomics

October 11, 2011
CenterWatch Staff

BioNanomatrix has changed its name to BioNano Genomics.  By adopting the new name, the company is communicating its position as a solution provider for genomics researchers who want to fully understand the biology of the genomes at the core of their research.  The change follows the recent establishment of new corporate headquarters in San Diego, the appointment of new leadership, and additional new investment.

The corporate re-branding reflects the company’s expanding focus on delivering genomic applications for its nanoAnalyzer system, a platform that uses single-molecule imaging to visualize extremely long nucleic acids and reveal genome architecture in its native state. BioNano Genomics makes full genome understanding more accessible to researchers and clinicians who seek simpler ways of examining whole genomes while extending their investigations beyond the realm of variation at the level of only a few nucleotides.

"The change reflects the next evolution of our company as we commercialize a platform that complements and extends the reach of existing genomic technologies by providing the long-range view of genomic variation," said BioNano Genomics president and CEO Dr. R. Erik Holmlin, "BioNano Genomics is intensely focused on helping the research community achieve a more comprehensive understanding of genome biology by developing insight into how the different components of a genome are organized.  This understanding should provide the context that has been missing in our understanding of the link between phenotypic variation and genomic variation."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing